Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 185 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Smoking addiction killed my grandfather – now it’s up to the... December 29, 2022 Women at High Risk of Breast Cancer Find it Hard to... April 22, 2021 Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma December 9, 2020 Cancer Research UK report highlights stark cancer inequalities across Scotland November 28, 2022 Load more HOT NEWS Ivosidenib and Azacitidine Combination Shows Significant Clinical Benefit in Patients with... My Path to Becoming a Radiation Therapist Withdrawal of Application for the EMA Marketing Authorisation of Infigratinib What Cancer Survivors Should Know About Survivorship Research: Expert Perspectives
